Malaria Vaccine Type | Usage | Precautions | Side Effects

Malaria Vaccine Type | Usage | Precautions | Side Effects

  • Malaria is caused by four or five species of a parasite Plasmodium.
    P.falciparum is the specie responsible for most of the severe cases of malaria.
  • The disease is endemic in mainly tropic and sub-tropic regions of the world, and is a major cause of morbidity and mortality globally.

Malaria Vaccine


  • Currently there is no vaccine available against malaria for commercial or routine use.
  • RTS, S/AS01 is the only vaccine against malaria which has completed phase 3 trials.
  • It is a recombinant protein based vaccine capable of providing protection against P.falciparum but not against P.vivax.
  • WHO has recommended pilot vaccination projects using RTS, S/AS01 in some areas of sub-Saharan Africa.
  • If licensed, this will be the first ever vaccine licensed against a disease caused by a parasite.

Effectiveness


  • Reports from the Phase 3 trials conducted on about 15000 children in various countries of Africa divided into two age groups (6-14 weeks and 5-17 months old) were published in April 2015.
  • These reports estimated the efficacy of the vaccine to be around 30% in preventing severe malaria, with variations among the two age groups.